Piper Sandler Reiterates Overweight on Bristol-Myers Squibb, Raises Price Target to $82

Piper Sandler analyst David Amsellem reiterates Bristol-Myers Squibb (NYSE:BMY) with a Overweight and raises the price target from $75 to $82.